New combo therapy shows promise for tough-to-treat leukemia
NCT ID NCT04848974
First seen Oct 31, 2025 · Last updated May 25, 2026 · Updated 21 times
Summary
This study tested a new drug called uproleselan added to two chemotherapy drugs (cladribine and low dose cytarabine) for people with a specific type of acute myeloid leukemia that developed after prior treatment. The goal was to find the safest dose and see how many patients achieved remission. 37 adults took part in this early-phase trial at MD Anderson Cancer Center.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.